Comparison Between Darbapoeitin Alpha and Roxadustat in CKD-related Anemia

Anemia is a common and debilitating complication of chronic kidney disease (CKD), affecting a significant proportion of patients worldwide. It is approximately twice as prevalent among ESKD patients compared to the general population. The prevalence of anemia increases across the advancing stages of CKD, with estimates anywhere from 7% to >50%. Study Design:

This prospective observational cohort study involved 35 hemodialysis patients at Electricity Hospital, Almaza, Cairo, who were randomly treated with either Roxadustat or Darbepoetin Alfa over 12 weeks. The study aims to assess whether Roxadustat use in the management of ESKD-related anemia results in improved iron profile and reduced iron needs compared with traditional treatment for ESKD-related anemia.

Inclusion criteria

• End-stage kidney disease-related anemia
• Hemodialysis-related anemia
• The mean of the two most recent Hemoglobin values before randomization was 10.5mg/dL or less

Exclusion criteria

• ESA treatment 12 weeks before transfusion
• RBC transfusion 8 weeks before transfusion
• IV iron transfusion 6 weeks before transfusion
• Known history of myelodysplastic syndrome
• Known history of multiple myeloma
• Known history of hereditary hematologic diseases
• Active bleeding or any cause of anemia unrelated to CKD
• NYHA Class III or IV congestive heart failure
• Liver disease, defined as ALT or AST 3x ULN or greater, or total bilirubin 1.5x ULN or greater
• Prior organ transplant